Literature DB >> 22171592

Comparison of cationic and amphipathic cell penetrating peptides for siRNA delivery and efficacy.

Robert H Mo1, Jennica L Zaro, Wei-Chiang Shen.   

Abstract

Cell penetrating n>an class="Chemical">peptides (CPPs) are short strands of arginine- and/or lysine-rich peptides (<30 amino acids) that use their cationic nature for efficient intracellular accumulation. CPPs have been used for small interfering RNA (siRNA) delivery by direct complexation with the siRNA anionic phosphate backbone. During this process, however, part of the CPP cationic charges are neutralized, and the resultant loss of free positive charges may substantially compromise CPP's internalization capabilities and eventually reduce siRNA delivery efficiency. The purpose of this study was to design a novel type of polyplex for siRNA delivery to overcome the CPP neutralization issue. This novel polyplex consists of three components: siRNA, 21mer oligolysine (K21) chemically modified to incorporate CPP conjugation sites (K21-PDP), and CPP delivery moiety. The siRNA was first neutralized by cationic charges of K21-PDP to form a polyplex. Then a cationic (hexaarginine, R6) or an amphipathic (model amphipathic peptide, MAP) CPP was conjugated to the polyplex. Agarose gel shift assays indicated that the siRNA could be released from the polyplex after K21-PDP degradation or polyplex dilution. Furthermore, the total intracellular internalization of these two CPP-polyplexes was studied. Compared with R6-polyplex, MAP-polyplex exhibited 170- and 600-fold greater uptake of fluorescently labeled siRNA at 1 and 6 h post-transfection, respectively. MAP-polyplex also exhibited comparable GFP silencing effects as Lipofectamine 2000 complex in Huh7.5 cells stably transfected to express GFP-light chain 3 protein, whereas R6-polyplex did not demonstrate significant silencing activity. Further studies indicated that the K21-PDP-siRNA polyplex formation and conjugation of MAP to the polyplex were essential for siRNA polyplex uptake and gene silencing. MAP-polyplex was also shown to be unaffected by the presence of 10% FBS during transfection. In addition, MAP-polyplex uptake was dependent on vesicle formation and fusion due to 70 and 54% loss of uptake at 4 and 16 °C, respectively, compared to incubation at 37 °C. Therefore, the amphipathic CPP is a more suitable carrier moiety for delivery of siRNA polyplex.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22171592      PMCID: PMC3273621          DOI: 10.1021/mp200481g

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  46 in total

1.  Evidence that membrane transduction of oligoarginine does not require vesicle formation.

Authors:  Jennica L Zaro; Wei-Chiang Shen
Journal:  Exp Cell Res       Date:  2005-03-29       Impact factor: 3.905

2.  A new potent secondary amphipathic cell-penetrating peptide for siRNA delivery into mammalian cells.

Authors:  Laurence Crombez; Gudrun Aldrian-Herrada; Karidia Konate; Quan N Nguyen; Gary K McMaster; Robert Brasseur; Frederic Heitz; Gilles Divita
Journal:  Mol Ther       Date:  2008-10-28       Impact factor: 11.454

3.  Rapid chemosensitivity testing of human lung tumor cells using the MTT assay.

Authors:  S P Cole
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

4.  A sensitive fluorometric method for the determination of arginine using 9,10-phenanthrenequinone.

Authors:  R E Smith; R MacQuarrie
Journal:  Anal Biochem       Date:  1978-10-01       Impact factor: 3.365

5.  Vectors based on reducible polycations facilitate intracellular release of nucleic acids.

Authors:  Martin L Read; K Helen Bremner; David Oupický; Nicola K Green; Peter F Searle; Leonard W Seymour
Journal:  J Gene Med       Date:  2003-03       Impact factor: 4.565

6.  Disulfide and thioether linked cytochrome c-oligoarginine conjugates in HeLa cells.

Authors:  Maureen P Barnes; Wei-Chiang Shen
Journal:  Int J Pharm       Date:  2008-11-19       Impact factor: 5.875

7.  Analysis of gene function in somatic mammalian cells using small interfering RNAs.

Authors:  Sayda M Elbashir; Jens Harborth; Klaus Weber; Thomas Tuschl
Journal:  Methods       Date:  2002-02       Impact factor: 3.608

8.  Mammalian cell penetration, siRNA transfection, and DNA transfection by supercharged proteins.

Authors:  Brian R McNaughton; James J Cronican; David B Thompson; David R Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-23       Impact factor: 11.205

9.  Cellular delivery of small interfering RNA by a non-covalently attached cell-penetrating peptide: quantitative analysis of uptake and biological effect.

Authors:  Sandra Veldhoen; Sandra D Laufer; Alexander Trampe; Tobias Restle
Journal:  Nucleic Acids Res       Date:  2006-11-28       Impact factor: 16.971

Review 10.  Harnessing in vivo siRNA delivery for drug discovery and therapeutic development.

Authors:  Frank Y Xie; Martin C Woodle; Patrick Y Lu
Journal:  Drug Discov Today       Date:  2006-01       Impact factor: 7.851

View more
  21 in total

Review 1.  Delivery materials for siRNA therapeutics.

Authors:  Rosemary Kanasty; Joseph Robert Dorkin; Arturo Vegas; Daniel Anderson
Journal:  Nat Mater       Date:  2013-11       Impact factor: 43.841

2.  Tumor targeting of a cell penetrating peptide by fusing with a pH-sensitive histidine-glutamate co-oligopeptide.

Authors:  Likun Fei; Li-Peng Yap; Peter S Conti; Wei-Chiang Shen; Jennica L Zaro
Journal:  Biomaterials       Date:  2014-02-06       Impact factor: 12.479

3.  A New Synthetic Peptide with In vitro Antibacterial Potential Against Escherichia coli O157:H7 and Methicillin-Resistant Staphylococcus aureus (MRSA).

Authors:  Y A Prada; F Guzmán; P Rondón; P Escobar; C Ortíz; D A Sierra; R Torres; E Mejía-Ospino
Journal:  Probiotics Antimicrob Proteins       Date:  2016-09       Impact factor: 4.609

4.  The Potential of Cell-Penetrating Peptides for mRNA Delivery to Cancer Cells.

Authors:  Yelee Kim; Hyosuk Kim; Eun Hye Kim; Hochung Jang; Yeongji Jang; Sung-Gil Chi; Yoosoo Yang; Sun Hwa Kim
Journal:  Pharmaceutics       Date:  2022-06-15       Impact factor: 6.525

5.  Polyarginine molecular weight determines transfection efficiency of calcium condensed complexes.

Authors:  Nabil A Alhakamy; Cory J Berkland
Journal:  Mol Pharm       Date:  2013-04-15       Impact factor: 4.939

6.  Development of cholesteryl peptide micelles for siRNA delivery.

Authors:  Bin Qin; Zhijin Chen; Wei Jin; Kun Cheng
Journal:  J Control Release       Date:  2013-08-19       Impact factor: 9.776

Review 7.  Imaging-guided delivery of RNAi for anticancer treatment.

Authors:  Junqing Wang; Peng Mi; Gan Lin; Yì Xiáng J Wáng; Gang Liu; Xiaoyuan Chen
Journal:  Adv Drug Deliv Rev       Date:  2016-01-22       Impact factor: 15.470

Review 8.  Noncovalently associated cell-penetrating peptides for gene delivery applications.

Authors:  Nabil A Alhakamy; Adane S Nigatu; Cory J Berkland; Joshua D Ramsey
Journal:  Ther Deliv       Date:  2013-06

9.  Peptide nanoparticle delivery of charge-neutral splice-switching morpholino oligonucleotides.

Authors:  Peter Järver; Eman M Zaghloul; Andrey A Arzumanov; Amer F Saleh; Graham McClorey; Suzan M Hammond; Mattias Hällbrink; Ülo Langel; C I Edvard Smith; Matthew J A Wood; Michael J Gait; Samir El Andaloussi
Journal:  Nucleic Acid Ther       Date:  2015-01-16       Impact factor: 5.486

Review 10.  Intracellular Delivery of Molecular Cargo Using Cell-Penetrating Peptides and the Combination Strategies.

Authors:  Hua Li; Tung Yu Tsui; Wenxue Ma
Journal:  Int J Mol Sci       Date:  2015-08-18       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.